166 related articles for article (PubMed ID: 31218454)
1. A pragmatic patient-reported outcome strategy for rare disease clinical trials: application of the EORTC item library to myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Bell JA; Galaznik A; Pompilus F; Strzok S; Bejar R; Scipione F; Fram RJ; Faller DV; Cano S; Marquis P
J Patient Rep Outcomes; 2019 Jun; 3(1):35. PubMed ID: 31218454
[TBL] [Abstract][Full Text] [Related]
2. Measuring patient-reported physical functioning and fatigue in myelodysplastic syndromes using a modular approach based on EORTC QLQ-C30.
Regnault A; Pompilus F; Ciesluk A; Mazerolle F; Bejar R; Fram RJ; Faller DV; Marquis P; Bell JA
J Patient Rep Outcomes; 2021 Jul; 5(1):60. PubMed ID: 34283303
[TBL] [Abstract][Full Text] [Related]
3. Mixed-methods research to support the use of new lymphoma-specific patient-reported symptom measures derived from the EORTC item library.
Markowitz JT; Mazerolle F; Lovell T; Hess LM; Abada PB; Regnault A; Payakachat N
J Patient Rep Outcomes; 2024 Jan; 8(1):8. PubMed ID: 38252198
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.
Stauder R; Lambert J; Desruol-Allardin S; Savre I; Gaugler L; Stojkov I; Siebert U; Chevrou-Séverac H
Eur J Haematol; 2020 May; 104(5):476-487. PubMed ID: 31985078
[TBL] [Abstract][Full Text] [Related]
5. Validated Instruments of Quality of Life (QOL) in Patients With Acute Myeloid Leukemia (AML) and Other Cancers.
Salas M; Henderson M; Wientzek-Fleischmann A; Islam Z; Tu N; Bilitou A; Elsharkawy M; Stellmacher U
Front Pharmacol; 2020; 11():1109. PubMed ID: 32792948
[TBL] [Abstract][Full Text] [Related]
6. The EORTC CAT Core-The computer adaptive version of the EORTC QLQ-C30 questionnaire.
Petersen MA; Aaronson NK; Arraras JI; Chie WC; Conroy T; Costantini A; Dirven L; Fayers P; Gamper EM; Giesinger JM; Habets EJJ; Hammerlid E; Helbostad J; Hjermstad MJ; Holzner B; Johnson C; Kemmler G; King MT; Kaasa S; Loge JH; Reijneveld JC; Singer S; Taphoorn MJB; Thamsborg LH; Tomaszewski KA; Velikova G; Verdonck-de Leeuw IM; Young T; Groenvold M;
Eur J Cancer; 2018 Sep; 100():8-16. PubMed ID: 29936066
[TBL] [Abstract][Full Text] [Related]
7. Qualitative study to characterize patient experience and relevance of patient-reported outcome measures for patients with metastatic synovial sarcoma.
Eliason L; Grant L; Francis A; Cardellino A; Culver K; Chawla SP; Arbuckle R; Pokras S
J Patient Rep Outcomes; 2022 May; 6(1):43. PubMed ID: 35507231
[TBL] [Abstract][Full Text] [Related]
8. Exploring the patient experience of locally advanced or metastatic pancreatic cancer to inform patient-reported outcomes assessment.
Herman JM; Kitchen H; Degboe A; Aldhouse NVJ; Trigg A; Hodgin M; Narang A; Johnson CD
Qual Life Res; 2019 Nov; 28(11):2929-2939. PubMed ID: 31273624
[TBL] [Abstract][Full Text] [Related]
9. Patients' experience of recurrent/metastatic head and neck squamous cell carcinoma and their perspective on the EORTC QLQ-C30 and QLQ-H&N35 questionnaires: a qualitative study.
Degboe A; Knight SL; Halling K; Trigg A; Al-Zubeidi T; Aldhouse N; Kitchen H; Wirth L; Rogers SN
J Patient Rep Outcomes; 2017; 2():33. PubMed ID: 30148250
[TBL] [Abstract][Full Text] [Related]
10. International field testing of the psychometric properties of an EORTC quality of life module for oral health: the EORTC QLQ-OH15.
Hjermstad MJ; Bergenmar M; Bjordal K; Fisher SE; Hofmeister D; Montel S; Nicolatou-Galitis O; Pinto M; Raber-Durlacher J; Singer S; Tomaszewska IM; Tomaszewski KA; Verdonck-de Leeuw I; Yarom N; Winstanley JB; Herlofson BB;
Support Care Cancer; 2016 Sep; 24(9):3915-24. PubMed ID: 27113466
[TBL] [Abstract][Full Text] [Related]
11. Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.
Edlin R; Connock M; Tubeuf S; Round J; Fry-Smith A; Hyde C; Greenheld W
Health Technol Assess; 2010 May; 14 Suppl 1():69-74. PubMed ID: 20507806
[TBL] [Abstract][Full Text] [Related]
12. The EORTC QLQ-LC13: a modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life.
Bergman B; Aaronson NK; Ahmedzai S; Kaasa S; Sullivan M
Eur J Cancer; 1994; 30A(5):635-42. PubMed ID: 8080679
[TBL] [Abstract][Full Text] [Related]
13. Choice of a patient-reported outcome measure for patients with anal cancer for use in cancer clinical trials and routine clinical practice: a mixed methods approach.
Gilbert A; Francischetto EO; Blazeby J; Holch P; Davidson S; Sebag-Montefiore D; Velikova G
Lancet; 2015 Feb; 385 Suppl 1():S38. PubMed ID: 26312860
[TBL] [Abstract][Full Text] [Related]
14. Assessment of change of quality of life in terminally ill patients under cancer pain management using the EORTC Core Quality of Life Questionnaire (QLQ-C30) in a Korean sample.
Park KU
Oncology; 2008; 74 Suppl 1():7-12. PubMed ID: 18758191
[TBL] [Abstract][Full Text] [Related]
15. QLU-C10D: a health state classification system for a multi-attribute utility measure based on the EORTC QLQ-C30.
King MT; Costa DS; Aaronson NK; Brazier JE; Cella DF; Fayers PM; Grimison P; Janda M; Kemmler G; Norman R; Pickard AS; Rowen D; Velikova G; Young TA; Viney R
Qual Life Res; 2016 Mar; 25(3):625-36. PubMed ID: 26790428
[TBL] [Abstract][Full Text] [Related]
16. Design and development of a disease-specific quality of life tool for patients with aplastic anaemia and/or paroxysmal nocturnal haemoglobinuria (QLQ-AA/PNH)-a report on phase III.
Niedeggen C; Singer S; Groth M; Petermann-Meyer A; Röth A; Schrezenmeier H; Höchsmann B; Brümmendorf TH; Panse J
Ann Hematol; 2019 Jul; 98(7):1547-1559. PubMed ID: 31115593
[TBL] [Abstract][Full Text] [Related]
17. The validity of EORTC QLQ-C30 fatigue scale in advanced cancer patients and cancer survivors.
Knobel H; Loge JH; Brenne E; Fayers P; Hjermstad MJ; Kaasa S
Palliat Med; 2003 Dec; 17(8):664-72. PubMed ID: 14694917
[TBL] [Abstract][Full Text] [Related]
18. Development of computerised adaptive testing (CAT) for the EORTC QLQ-C30 dimensions - general approach and initial results for physical functioning.
Petersen MA; Groenvold M; Aaronson NK; Chie WC; Conroy T; Costantini A; Fayers P; Helbostad J; Holzner B; Kaasa S; Singer S; Velikova G; Young T;
Eur J Cancer; 2010 May; 46(8):1352-8. PubMed ID: 20231085
[TBL] [Abstract][Full Text] [Related]
19. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): an international, observational field study.
Koller M; Shamieh O; Hjermstad MJ; Hornslien K; Young T; Chalk T; Ioannidis G; Harle A; Johnson CD; Tomaszewski KA; Serpentini S; Pinto M; van der Weijst L; Janssens A; Morag O; Chie WC; Arraras JI; Pompili C; Jungraithmayr W; Hechtner M; Katsochi D; Müller K; Gräfenstein L; Schulz C; Bottomley A; ; ;
Lancet Oncol; 2020 May; 21(5):723-732. PubMed ID: 32213338
[TBL] [Abstract][Full Text] [Related]
20. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
